Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

ID
Name
CA180-597
Description
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.
Trial arms
Trial start
2015-07-31
Estimated PCD
2022-05-15
Trial end
2022-05-15
Status
Completed
Phase
Early phase I
Treatment
Dasatinib
Arms:
Dasatinib
Size
17
Primary endpoint
Number of Participants Who Received Dasatinib Treatment
From first dose on this study (CA180-597) to last dose on this study (up to approximately 76 months)
Duration of Treatment
From first dose on this study (CA180-597) to last dose on this study (up to approximately 76 months)
Eligibility criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Participated in and completed a previous dasatinib protocol (including but not limited to CA180056, CA180363 or CA180227) and is deemed by the investigator to be deriving benefit from dasatinib as defined by the previous protocol * Receiving dasatinib at the time of signature of informed consent * Males and Females, ages 18 and older Exclusion Criteria: * All patients previously discontinued from a dasatinib study for any reason * Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy * History of allergy to dasatinib
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 17, 'type': 'ACTUAL'}}
Updated at
2023-05-06

1 organization

1 product

1 indication

Organization
Bristol-Myers Squibb
Product
Dasatinib
Indication
Cancer